港股異動 | 歸創通橋-B(2190.HK)漲超12% 較近一個月低點已反彈超23%
格隆匯5月12日丨歸創通橋-B(2190.HK)持續走高,現大漲12.11%報12.96港元,最新市值43億港元;該股近期持續反彈,現價較近一個月的低點10.52港元已累漲超23%。歸創通橋曾於4月12日宣佈,公司自主研發的用於外周血管系統的經皮腔內血管成形術(PTA)的大直徑PTA球囊擴張導管已按計劃獲得中國國家藥監局的上市批准。這是國內首個獲得國家藥監局批准的國產研發的大直徑PTA球囊擴張導管產品,也是公司2022年從國家藥監局獲得的第二個批准。此外據悉,歸創通橋2021年度收入同比大增543.9%至1.78億元,毛利率升至74.1%,研發管線取得重大進展。天風證券認為公司2021年為商業化元年業績超預期,未來隨着產品逐步上市,收入和利潤有望維持較高增長,維持“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.